Recombinant constructs for screening drugs against the SARS-CoV-2 spike protein

The trypsin/trypsin-like protease-based SARS-CoV-2 spike protein cleavage assay system using recombinant constructs addresses the need for efficient drug screening by enabling rapid detection of protease activity, facilitating safer and faster drug development.

JP2024541032APending Publication Date: 2024-11-06COUNCIL OF SCI & IND RES
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
JP2024525341
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-10-28
Filing Date
2022-10-27
Publication Date
2024-11-06

AI Technical Summary

Technical Problem

Current methods lack an efficient in vitro system for screening drugs targeting trypsin-like proteases that facilitate SARS-CoV-2 spike protein cleavage, which is crucial for viral entry into host cells.

Method used

Development of a trypsin/trypsin-like protease-based SARS-CoV-2 spike protein cleavage assay system using recombinant constructs, including a substrate with a reporter protein, cellulose binding domain, and a hexahistidine tag, which allows for easy purification and detection of cleavage through bioluminescent signals.

Benefits of technology

The assay system efficiently screens drugs by detecting protease activity, is easy to interpret, and can be scaled to high-throughput, reducing reliance on animal or human cell cultures and providing a safer, faster drug screening method.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024541032000003
    Figure 2024541032000003
  • Figure 2024541032000004
    Figure 2024541032000004
  • Figure 2024541032000005
    Figure 2024541032000005
Patent Text Reader

Abstract

Trypsin / trypsin-like proteases have been reported to aid in the entry of SARS-CoV-2 into host cells. The spike has a protease cleavage site between the S1 and S2 domains. The cleavage properties of the proteases can be used to design drug screening assays to screen antiviral candidates against spike cleavage. In the claimed invention, we have developed a proof-of-concept assay system to screen drugs against proteases that cleave the spike between S1 and S2. We have designed a fusion substrate protein that contains a reporter protein, a protease cleavage site between S1 and S2, and a cellulose binding domain. The presence of the cellulose binding domain (CBD) allows the substrate protein to be anchored to cellulose. When the protease cleaves the substrate, the reporter protein is removed while the CBD remains bound to cellulose. The released reporter can be used as a readout for protease activity.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to the development of a reporter-based in vitro trypsin / trypsin-like protease-based SARS-CoV-2 spike protein cleavage assay system, which includes a recombinant construct for screening drugs against the SARS-CoV-2 spike protein. [Background technology]

[0002] Trypsin-like proteases are known to play a key role in facilitating coronavirus infection (SARS-CoV, SARS-CoV2, MERS-CoV, etc.) [1-4]. These enzymes cleave the spike protein to facilitate its interaction with the host receptor for cell entry. Coronaviruses are known to have specific cleavage sites, called S1 / S2 and S2 / S2', which are specifically recognized by airway proteases for further processing. Kam et al. [2] and Weber et al. [1] studied SARS-CoV and MERS-CoV, respectively, to identify potential protease cleavage sites in the spike protein and were able to identify two sites (S1 / S2 and S2 / S2') responsible for proteolytic processing. SARS-CoV2 spike is also known to have these two sites as well as a special polybasic cleavage site near S1 / S2, which is susceptible to recognition by different proteases [3,4,5]. According to Hoffmann et al., in the SARS-CoV-2 spike, the S1 / S2 cleavage site is located at residues 676 to 688, and the S2' site is located at residues 811 to 818, which are similar to the SARS-CoV and MERS-CoV spike cleavage sequences [1,2,4]. Airway serine proteases such as trypsin are known to be important in mediating influenza A virus infection by cleaving its envelope glycoprotein, and have also been shown to recognize and cleave the SARS-CoV and SARS-CoV2 spike [2,5]. Other serine proteases, such as the type II transmembrane serine protease TTSP, have been extensively studied as being important in processing the coronavirus spike protein and enhancing its infectivity [1-4]. Similarly, there are other proteases, such as furin and cathepsins, that are also known to cleave the SARS-CoV2 spike protein in regions specific for its downstream processing [5]. Therefore, airway proteases and trypsin-like proteases play important roles in enhancing the viral infectivity of coronaviruses and may be potential targets for antiviral therapy in the near future. Summary of the Invention

[0003] The main objective of the present invention is to develop a reporter-based in vitro trypsin / trypsin-like protease-based SARS-CoV-2 spike protein cleavage assay system, which includes a recombinant construct for screening drugs against SARS-CoV-2 spike protein. Yet another object of the invention is a substrate for use in the claimed assay system for trypsin / trypsin-like protease cleavage activity.

[0004] Thus, the present invention provides a reporter-based in vitro trypsin / trypsin-like protease-based SARS-CoV-2 spike protein cleavage assay system, which includes a recombinant construct for screening drugs against SARS-CoV-2 spike protein. In an embodiment of the present invention, a substrate is designed and used that contains the trypsin / trypsin-like protease cleavage domain of the SARS-CoV-2 spike protein, a reporter protein, and a cellulose binding domain. The substrate also has a hexahistidine tag at one end for protein purification purposes. A methionine was added to the N-terminus of the hexahistidine for protein expression. The DNA construct corresponding to the substrate is globally codon-modified for expression in bacterial systems. In an embodiment of the invention, the claimed substrates used in the assay system are cleaved by trypsin / trypsin-like proteases, the cellulose matrix / slurry captures the cellulose binding domains and the reporter protein is released from the cleaved substrate, which can then be detected using a reporter assay. In another embodiment of the present invention, the reporter used to design the substrate is nanoluciferase. Alternatively, other luciferases as well as fluorescent reporters may be used. The Nanoluc luciferase used in the construct is a novel bioluminescent protein with better light emission ability and enhanced physical and biochemical properties [6]. Its specific activity is greater than other luciferases previously reported (e.g., firefly or Renilla). Due to its high sensitivity, Nanoluc luciferase can elicit bioluminescent signals even at very low doses compared to other luciferases. The designed construct is very powerful in expressing bioluminescence when cleaved by specific enzyme. The designed assay system is based on the principle that the more efficiently the enzyme cleaves the substrate, the more bioluminescent signal is generated, and if any enzyme-specific inhibitor is introduced, the signal will decrease in proportion to the amount of drug used.

[0005] Abbreviation SARS-CoV-2 Severe Acute Respiratory Syndrome Coronavirus 2 MERS Middle East Respiratory Syndrome CBD Cellulose Binding Domain SDS-PAGE Sodium dodecyl sulfate polyacrylamide gel electrophoresis TBST Tris-buffered saline Tween 20 TMPRSS2 Transmembrane serine protease 2 CM Camostat mesilate CB Cathepsin B [Brief description of the drawings]

[0006] [Figure 1] FIG. 1 is a schematic diagram illustrating the principle of the claimed assay system. [Diagram 2] FIG. 2 is a schematic showing the various cleavage patterns that, once proteases have cleaved the spike protein, can be acquired and visualized on an SDS-PAGE gel stained with a protein dye. [Diagram 3]FIG. 3 shows a schematic diagram of the substrate design used in the assay system and a vector map of the cloned substrates. [Figure 4] FIG. 4 is a verification of the substrate expression plasmid using restriction digestion. [Diagram 5] FIG. 5 shows the purified substrate protein on an SDS-PSGE gel stained with a protein dye. [Figure 6] Figure 6: Validation of the purified substrate by Western blot analysis using anti-SARS-CoV-2 S1 / S2 and anti-His antibodies. [Figure 7] FIG. 7 shows the results of a cleavage assay based on the nanoluciferase assay using the claimed substrate and trypsin enzyme. [Figure 8] FIG. 8 shows the results of a gel-based cleavage assay using the claimed substrate and trypsin enzyme. [Figure 9] FIG. 9 shows substrates treated with different amounts of TMPRSS2. [Figure 10] Figure 10 shows substrate digestion with TMPRSS2 (nanoluciferase assay) in the absence and presence of two different amounts of camostat mesylate (TMPRSS2 inhibitor). CM = camostat mesylate. [Figure 11] Figure 11 shows SES-PAGE gels of substrates treated with different units of furin (50-800 mU) for 4 hours at 25°C. PL=protein ladder, S=substrate, F=furin, BF—BSA digested with furin, F50-F80=different amounts of furin. [Figure 12] FIG. 12 shows that the substrate was digested with Furin (nanoluciferase assay) in the absence and presence of two different amounts of Furin inhibitor II (Furin inhibitor). [Figure 13] Figure 13 shows the results of a Nanoluc luciferase assay in which the substrate was digested with different amounts of cathepsin B for 2 hours at 37°C. CB = cathepsin B. [Figure 14] Figure 14. Effect of cathepsin B inhibitors on substrate digestion. CI = cathepsin B inhibitor. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0007] Mechanism of Action of the Claimed Drug Screening Assay System All substrates contain the reporter protein as a fusion protein, followed by the spike protein cleavage sequence and the cellulose binding domain [Figure 1]. Upon addition of a trypsin-like protease, the substrate is cleaved at the cleavage site and the reporter protein is removed. When cellulose from a cellulose matrix / slurry is added to this reaction mixture, it binds to the cellulose binding domain and the reporter protein is available for the reporter assay from the reaction supernatant. A clear reporter signal indicates cleavage by the protease. The cleavage bands can also be visualized on SDS-PAGE after staining with a protein staining dye or Western blot analysis [Figure 2]. Practicality of the assay system The assay system can be used to screen drugs against trypsin / trypsin-like proteases that cleave the SARS-CoV-2 spike protein. This cleavage is important for the virus' entry process into its host cells, and the claimed drug screening assay system can be used to screen drugs against the function of trypsin / trypsin-like proteases in cleaving the spike protein. The drugs are selected from the group consisting of camostat mesylate, cathepsin B inhibitor, furin inhibitor II, protease inhibitor, furin inhibitor I, trypsin inhibitor, ovomucoid, Kunitz trypsin inhibitor, serine protease inhibitor, and TMPRSS2 inhibitor. The designed constructs can be useful to identify cleavage sites of proteases not yet known to cleave the spike. They can also be used to identify whether other unknown host proteases are involved in spike protein cleavage. The designed assay system is easy to understand and interpret and does not involve complicated steps. EXAMPLES

[0008] The following examples are given by way of illustration of the present invention and should not be construed as limiting the scope of the invention. Example 1 Reporter-based substrate DNA: construct design and cloning The designed gene sequence was codon-optimized for expression in a bacterial expression system, and the entire fusion insert was cloned between the restriction enzyme sites NdeI and HindIII of the bacterial expression vector pET30a [Figures 3 and 4]. Details regarding the cloning are as follows. The substrate DNA to be designed (SEQ ID NO: 2) (URSCREENSARS-CoV-2BactDNA) consists of a start codon (methionine)-polyhis tag (6x)-reporter construct (nanoluciferase) (SEQ ID NO: 3) (URSCREENSARS-CoV2NanoLucDNA)-protease cleavage site (SEQ ID NO: 4) (URSCREENSARS-CoV2 cleavage site DNA)-cellulose binding domain (SEQ ID NO: 5) (URSCREENSARS-CoV2CBDDNA)-stop codon [Figure 3]. The accession number of the source gene sequence used for nanoluciferase is AIS23666[6]. The accession number of the source gene sequence used for the cellulose-binding domain is CAA48312.1 [7]. The accession number of the source gene sequence used for the protease cleavage site is YP_009724390.1 [8]. A start codon, methionine, was introduced into the sequence so that protein translation could begin. Following the methionine, a hexahistidine residue was introduced for purification of the expressed protein. Two stop codons (TAG and TAA) were introduced at the 3' end of the cellulose binding domain sequence. A cleavage site for the restriction endonuclease Nde1 was introduced at the 5' end of the sequence preceding the methionine start codon. Since the restriction enzyme cleavage site is CATATG and the remaining part, i.e., ATG, can be used as the start codon, all that was required was to add three extra nucleotides (CAT) before the ATG. A cleavage site for the restriction endonuclease HindIII (AAGCTT) was introduced at the 3' end of the sequence after the stop codon. The entire fusion gene was codon-optimized for bacterial expression using IDT tools (Integrated DNA technologies, Inc.) and the CLUSTAL OMEGA tools were used to align the (original and codon-optimized) sequences and confirm any changes in the final protein expression. The gene sequence was inserted between the NdeI and HindIII restriction sites of the bacterial expression vector Pet30a+. Cloning was further verified by restriction digestion of plasmid DNA using NdeI and HindIII restriction enzymes.

[0009] Example 2 Expression and purification of substrate proteins We expressed the substrate protein (SEQ ID NO:1) (URSCREENSARS-CoV-2) in E. coli Nico21 competent cells (obtained from New England Biolabs, 240 Country Road, Ipswich, MA 01938-2723, USA) and purified it using Ni-NTA purification technique. The substrate could be purified from the soluble fraction. The substrate expression plasmid was transformed in Nico21 cells and cultured on LB-Kan plates. The plates were incubated overnight at 37°C and one of the transformed colonies was added to 2 ml of selective medium (primary inoculation). After 4–6 h of incubation, a secondary inoculation was performed in a 200 ml culture and the culture was grown until the OD600 reached 0.4–0.5. The culture was then induced by adding 0.5 mM IPTG and incubated for 16 h at 15°C under shaking conditions. After incubation, the cells were harvested by centrifuging the culture at 4°C. Cells were resuspended in 20 ml of cell lysis buffer (50 mM NaH2PO4, 300 mM NaCl, 10 mM imidazole, pH 8) and sonicated (30 amps, 20 sec on, 20 sec off, 60 min). Soluble (cytoplasmic) and insoluble (inclusion bodies and debris) fractions were separated by centrifugation of the lysate at 15000g for 30 min at 4 degrees. The pellet and supernatant were run on a 10% separating SDS-PAGE gel (with 4% stacking) to confirm protein expression. The gel was run at 70V for 15 min and then at 110V until the protein ladder was resolved. The gel was stained with Simply Blue gel stain (Invitrogen) and visualized with ChemiDoc. The resulting soluble fraction was used to purify the protein on a Ni-NTA column (Qiagen). First, the column was placed in a QIArack at room temperature to allow the resin to settle to the end of the column. The cap was broken before opening and storage buffer was allowed to flow through. The column was equilibrated by adding 10 ml of binding buffer (the binding buffer used was the same as the cell lysis buffer) and allowed to flow through by gravity. The soluble fraction was added to the column and left for 5 minutes before being allowed to flow through. The column was washed using wash buffer and the protein was eluted using elution buffer.The wash and elution buffers contained 20 mM imidazole and 250 mM imidazole, respectively, and maintained the same static conditions as the cell lysis buffer. After purification, the protein was dialyzed overnight at 4°C in dialysis buffer (50 mM Tris, pH 7.4, 100 mM KCl, 20% glycerol, 7 mM beta-mercaptoethanol). The dialyzed protein was run on SDS-PAGE and confirmed using gel staining [Figure 5]. It was aliquoted into multiple tubes and stored at -80°C. Western blot analysis using anti-SARS-CoV2 S1 / S2 and anti-His antibodies was also used to verify the purified substrate protein [Figure 6]. The purified protein was loaded onto a 10% separating SDS-PAGE gel (using 4% stacking) with SDS gel loading dye. The gel was run at 70 V for 15 min, then at 110 V until the ladder separated. The gel was transferred onto a nitrocellulose membrane (pore size 0.45 μm) in transfer buffer (190 mM glycine, 25 mM Tris, pH 8.3, 200 ml methanol) at 400 mA and 4 °C for 2 h. The blot was stained using Ponceau stain (1% Ponceau stain in 5% acetic acid) to visualize the transfer. After confirmation of protein transfer, the membrane was blocked using 5% skim milk in TBST buffer (20 mM Tris, 150 mM NaCl, 0.1% Tween 20, Ph 7.6) at room temperature for 2 hours with slow shaking. Primary antibody (anti-SARS-CoV2 S2 / S2' site produced in rabbit, Gene Tex GTX135386, diluted 1:1000 in 5% blocking solution) (or anti-His antibody) was added to the blot and incubated at 4°C for 14 hours with slow shaking. The blot was further incubated in the primary antibody at room temperature for 15 minutes with shaking, and then washed three times with TBST buffer for 5 minutes with fast shaking. The blot was then incubated with secondary antibody (anti-rabbit IgG produced in goat, NBP175346, 1:5000 in TBST buffer) at room temperature for 1 hour with slow shaking. The washing step was repeated. Blots were developed in ChemiDoc using Clarity's ECL substrate.

[0010] Example 3 Cleavage assay We first used trypsin to confirm whether the substrate was cleaved and whether the luciferase was active. We used cellulose slurry (Sigmacell cellulose type 50 was used to make a slurry in buffer and used in the reaction at a slurry composition of 33% w / v) to capture the cellulose-binding domain of the substrate after trypsinization followed by centrifugation and collection of the supernatant. Luminescence was recorded. More luciferase activity was observed in the case of the enzyme-treated substrate compared to the substrate without enzyme treatment. This assay was performed in triplicate for five independent runs to ensure reproducibility. Thus, our substrate was proven to be active [Figure 7]. To further confirm the cleavage of the substrate, we also performed the cleavage assay reaction (reacted in 50 μl of 0.1 M Tris, pH 7.45 at 37°C for 1 h) on 15% SDS-PAGE. Bovine serum albumin (BSA) was used as a control to confirm whether the cleavage was nonspecific. After gel electrophoresis, the gel was stained with Sypro Ruby protein stain. We could clearly see the cleavage bands of the predicted molecular weights after gel staining [Figure 8]. Therefore, we confirmed the substrate cleavage by using both visual analysis as well as luciferase assay. In addition, we have validated our assay system using a few other proteases, namely TMPRSS2 [Figures 9, 10], Furin [Figures 11, 12] and Cathepsin B [Figures 13, 14]. We have also used inhibitors of these proteases, demonstrating that the enzyme activity is indeed inhibited when the inhibitors are used. Typical results are obtained with each additional enzyme tested.

[0011] Below, the luciferase assay is explored to scale up this assay system to a high throughput format. 1. Design a concept of the mechanism of action of the assay system. 2. Design a fusion protein construct for the substrate to be used in the assay system. 3. Codon modifying substrate coding DNA for expression in bacteria. 4. Cloning of the substrate gene in a bacterial expression plasmid and expression of the substrate protein followed by purification from the bacterial culture. 5. Verify substrate cleavage by trypsin / trypsin-like proteases using trypsin, TMPRSS2, furin and cathepsin B as representative enzymes. 6. Validate the cleavage assay by both gel-based detection as well as by reporter assay.

[0012] advantage 1. An in vitro assay system. 2. The substrate is purified from bacterial culture, making it easy to purify. 3. The substrate cleavage assay does not require animal or human cell cultures. 4. The assay system is safe because no infectious viruses are involved. 5. The assay system is an independent animal cell culture, so it is less time consuming. 6. The assay system can be upgraded to a high-throughput system, which is helpful for screening a large number of drugs at one time. 7. It can also be used to identify whether other unknown host proteases are involved in spike protein cleavage. The designed assay system is easy to understand and interpret, and does not involve complicated steps. [References] TIFF2024541032000001.tif156155 TIFF2024541032000002.tif115152

Claims

1. A recombinant construct for screening drugs against the SARS-CoV-2 spike protein having SEQ ID NO:

2.

2. (i) a fusion protein having SEQ ID NO:1; (ii) a designed substrate; (iii) a reporter protein; The recombinant construct of claim 1 , comprising:

3. 3. The recombinant construct of claim 2, wherein the designed substrate has a hexahistidine tag at one end for protein purification.

4. 3. The recombinant construct of claim 2, wherein a methionine is added to the N-terminus of the hexahistidine.

5. The reporter protein is (a) a methionine initiation codon at the N-terminus of a hexahistidine residue; (b) two stop codons at the 3' end of the cellulose binding domain sequence; The recombinant construct of claim 2, comprising:

6. a. a reporter protein having SEQ ID NO:3; b. a spike protein cleavage sequence having SEQ ID NO:4; c. a cellulose binding domain having SEQ ID NO:5; The fusion protein of claim 2, comprising:

7. i. providing a fusion protein having SEQ ID NO:1; ii. adding a trypsin-like protease and a test subject drug to the fusion protein obtained in step (i) to obtain a reaction mixture; iii. Providing a cellulose matrix / slurry; iv. mixing the reaction mixture obtained in step (ii) with the cellulose matrix obtained in step (iii); v. centrifuging the mixture obtained in step (iv) to obtain the reporter protein from the reaction supernatant for reporter assay; vi. measuring the reporter signal, where a decrease in reporter signal compared to a control without inhibitor confirms positive activity of the agent being screened; An in vitro assay system for screening drugs against SARS-CoV-2, comprising:

8. The in vitro assay system of claim 7, wherein the drug is selected from the group consisting of camostat mesylate, cathepsin B inhibitor, furin inhibitor II, protease inhibitor, furin inhibitor I, trypsin inhibitor, ovomucoid, Kunitz trypsin inhibitor, serine protease inhibitor, TMPRSS2 inhibitor.

9. 8. The in vitro assay system of claim 7, wherein the cellulose matrix is ​​composed of cellulose in a buffer used for the reaction in a 33% w / v slurry composition.

10. 8. The in vitro assay system of claim 7, wherein the reporter protein is selected from the group consisting of luciferase and a fluorescent reporter.

Citation Information

Patent Citations

  • Novel "Cleave-N-Read" system for protease activity assay and methods of use thereof

    US20050214890A1

  • Targeted chondroitinase abc fusion proteins and complexes thereof

    WO2020087051A1

  • Identification and use of compounds in the treatment or prevention of severe acute respiratory syndrome coronavirus 2

    WO2021195470A2